Holders — by stockHoldings — by fund
Omega Fund Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001637359
$185.7M
disclosed book value
10
positions
29.1%
largest position share
Positions, as of 2026-06-30
top 10 of 10 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | BCAXBicara Therapeutics Inc. | 1.8M | $54.1M | 29.1% |
| 2 | NUVBNuvation Bio Inc. | 8.1M | $45.9M | 24.7% |
| 3 | Kestra Med Technologies Ltd | 1.0M | $26.0M | 14% |
| 4 | BBOTBridgeBio Oncology Therapeutics Inc. | 3.3M | $25.1M | 13.5% |
| 5 | BBNXBeta Bionics Inc. | 1.3M | $20.6M | 11.1% |
| 6 | ALMSAlumis Inc. | 241,255 | $6.8M | 3.7% |
| 7 | SANASana Biotechnology, Inc. | 843,750 | $2.9M | 1.6% |
| 8 | IMAImageneBio, Inc. | 455,361 | $2.7M | 1.4% |
| 9 | enGene Holdings Inc. | 876,357 | $1.5M | 0.8% |
| 10 | ODTXOdyssey Therapeutics Inc. | 2,893 | $54,128 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.